Dr. Sarah Hoffe, section head of Gastrointestinal Radiation Oncology, presented about the GRECO-2 trial at the 2021 annual American Society of Clinical Oncology meeting.
Locally advanced or borderline resectable cancers continue to have a difficult prognosis. While systemic treatment of pancreatic cancer has improved, rates of surgical resection - considered optimum treatment - remain low. Patients with un-resectable or borderline pancreatic cancer still have poor outcomes, with both toxicity and disease progression during induction chemotherapy limiting the number eligible for surgery.
GRECO-2 is a phase 2, multicenter, randomized, double-blind, placebo-controlled study to determine the effect on overall survival of adding GC4711 to SBRT following 4 months of chemotherapy in subjects with un-resectable or borderline non-metastatic pancreatic cancer. The GRECO-2 trial will investigate a new class of modifiers that may be helpful in improving the radiation response of primary pancreatic cancer while also protecting normal tissue.
"We're very excited since pancreatic cancer continues to be such a difficult disease and we always want to expand treatment options for patients."
Moffitt was one of the high-volume centers with the last trial, which showed improved outcomes for these patients.
GRECO-2 will be open at Moffitt in the very near future and researchers are hopeful that this current phase of the trial will show similar results.
View the abstract for more information about this study.
Learn more about Moffitt's Gastrointestinal Oncology Program.